GABA B receptor-positive modulators: Enhancement of GABA B receptor agonist effects in vivo

Wouter Koek, Charles P France, Kejun Cheng, Kenner C. Rice

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

In vivo effects of GABA B receptor-positive modulators suggest that they have therapeutic potential for treating central nervous system disorders such as anxiety, depression, and drug abuse. Although these effects generally are thought to be mediated by positive modulation of GABA B receptors, such modulation has been examined primarily in vitro. The present study was aimed at further examining the in vivo positive modulatory properties of the GABA B receptor-positive modulators, 2,6-di-tert-butyl-4-(3- hydroxy-2,2-dimethylpropyl) phenol (CGP7930) and (R,S)-5,7-di-tert-butyl-3- hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF). Both compounds enhanced loss of righting induced by baclofen in mice. However, CGP7930 was less effective and rac-BHFF was less potent for enhancing loss of righting induced by γ-hydroxybutyrate (GHB), which, like baclofen, has GABA B receptor agonist properties. In contrast with baclofen- and GHB-induced loss of righting, the hypothermic effects of baclofen and GHB were not enhanced by rac-BHFF but were enhanced by CGP7930 only at doses that produced hypothermia when given alone. CGP7930-induced hypothermia was not attenuated by the GABA B receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348), at doses that blocked baclofen-induced hypothermia, and was not increased by the nitric-oxide synthase inhibitor N ω-nitro-L- arginine methyl ester, at doses that increased the hypothermic effects of baclofen and GHB. The results provide evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABA B receptors mediating loss of righting, but not at GABA B receptors mediating hypothermia. Conceivably, CGP7930, but not rac-BHFF, acts as an allosteric agonist at these latter receptors. Taken together, the results provide further evidence of pharmacologically distinct GABA B receptor subtypes, possibly allowing for a more selective therapeutic interference with the GABA B system.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume335
Issue number1
DOIs
StatePublished - Oct 2010

Fingerprint

GABA-B Receptor Agonists
GABA-B Receptors
Baclofen
Induced Hypothermia
Hypothermia
GABA-B Receptor Antagonists
Hydroxybutyrates
Central Nervous System Diseases
2,6-di-tert-butyl-4-(3-hydroxy-2,2-dimethylpropyl)phenol
Nitric Oxide Synthase
gamma-Aminobutyric Acid
Substance-Related Disorders
(R,S)-5,7-di-tert-butyl-3-hydroxy-3-trifluoromethyl-3H-benzofuran-2-one
Anxiety
Depression
Therapeutics

ASJC Scopus subject areas

  • Pharmacology
  • Molecular Medicine
  • Medicine(all)

Cite this

GABA B receptor-positive modulators : Enhancement of GABA B receptor agonist effects in vivo. / Koek, Wouter; France, Charles P; Cheng, Kejun; Rice, Kenner C.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 335, No. 1, 10.2010, p. 163-171.

Research output: Contribution to journalArticle

@article{4a4943b033094e07af5ae142b6124385,
title = "GABA B receptor-positive modulators: Enhancement of GABA B receptor agonist effects in vivo",
abstract = "In vivo effects of GABA B receptor-positive modulators suggest that they have therapeutic potential for treating central nervous system disorders such as anxiety, depression, and drug abuse. Although these effects generally are thought to be mediated by positive modulation of GABA B receptors, such modulation has been examined primarily in vitro. The present study was aimed at further examining the in vivo positive modulatory properties of the GABA B receptor-positive modulators, 2,6-di-tert-butyl-4-(3- hydroxy-2,2-dimethylpropyl) phenol (CGP7930) and (R,S)-5,7-di-tert-butyl-3- hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF). Both compounds enhanced loss of righting induced by baclofen in mice. However, CGP7930 was less effective and rac-BHFF was less potent for enhancing loss of righting induced by γ-hydroxybutyrate (GHB), which, like baclofen, has GABA B receptor agonist properties. In contrast with baclofen- and GHB-induced loss of righting, the hypothermic effects of baclofen and GHB were not enhanced by rac-BHFF but were enhanced by CGP7930 only at doses that produced hypothermia when given alone. CGP7930-induced hypothermia was not attenuated by the GABA B receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348), at doses that blocked baclofen-induced hypothermia, and was not increased by the nitric-oxide synthase inhibitor N ω-nitro-L- arginine methyl ester, at doses that increased the hypothermic effects of baclofen and GHB. The results provide evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABA B receptors mediating loss of righting, but not at GABA B receptors mediating hypothermia. Conceivably, CGP7930, but not rac-BHFF, acts as an allosteric agonist at these latter receptors. Taken together, the results provide further evidence of pharmacologically distinct GABA B receptor subtypes, possibly allowing for a more selective therapeutic interference with the GABA B system.",
author = "Wouter Koek and France, {Charles P} and Kejun Cheng and Rice, {Kenner C.}",
year = "2010",
month = "10",
doi = "10.1124/jpet.110.171116",
language = "English (US)",
volume = "335",
pages = "163--171",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - GABA B receptor-positive modulators

T2 - Enhancement of GABA B receptor agonist effects in vivo

AU - Koek, Wouter

AU - France, Charles P

AU - Cheng, Kejun

AU - Rice, Kenner C.

PY - 2010/10

Y1 - 2010/10

N2 - In vivo effects of GABA B receptor-positive modulators suggest that they have therapeutic potential for treating central nervous system disorders such as anxiety, depression, and drug abuse. Although these effects generally are thought to be mediated by positive modulation of GABA B receptors, such modulation has been examined primarily in vitro. The present study was aimed at further examining the in vivo positive modulatory properties of the GABA B receptor-positive modulators, 2,6-di-tert-butyl-4-(3- hydroxy-2,2-dimethylpropyl) phenol (CGP7930) and (R,S)-5,7-di-tert-butyl-3- hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF). Both compounds enhanced loss of righting induced by baclofen in mice. However, CGP7930 was less effective and rac-BHFF was less potent for enhancing loss of righting induced by γ-hydroxybutyrate (GHB), which, like baclofen, has GABA B receptor agonist properties. In contrast with baclofen- and GHB-induced loss of righting, the hypothermic effects of baclofen and GHB were not enhanced by rac-BHFF but were enhanced by CGP7930 only at doses that produced hypothermia when given alone. CGP7930-induced hypothermia was not attenuated by the GABA B receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348), at doses that blocked baclofen-induced hypothermia, and was not increased by the nitric-oxide synthase inhibitor N ω-nitro-L- arginine methyl ester, at doses that increased the hypothermic effects of baclofen and GHB. The results provide evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABA B receptors mediating loss of righting, but not at GABA B receptors mediating hypothermia. Conceivably, CGP7930, but not rac-BHFF, acts as an allosteric agonist at these latter receptors. Taken together, the results provide further evidence of pharmacologically distinct GABA B receptor subtypes, possibly allowing for a more selective therapeutic interference with the GABA B system.

AB - In vivo effects of GABA B receptor-positive modulators suggest that they have therapeutic potential for treating central nervous system disorders such as anxiety, depression, and drug abuse. Although these effects generally are thought to be mediated by positive modulation of GABA B receptors, such modulation has been examined primarily in vitro. The present study was aimed at further examining the in vivo positive modulatory properties of the GABA B receptor-positive modulators, 2,6-di-tert-butyl-4-(3- hydroxy-2,2-dimethylpropyl) phenol (CGP7930) and (R,S)-5,7-di-tert-butyl-3- hydroxy-3-trifluoromethyl-3H-benzofuran-2-one (rac-BHFF). Both compounds enhanced loss of righting induced by baclofen in mice. However, CGP7930 was less effective and rac-BHFF was less potent for enhancing loss of righting induced by γ-hydroxybutyrate (GHB), which, like baclofen, has GABA B receptor agonist properties. In contrast with baclofen- and GHB-induced loss of righting, the hypothermic effects of baclofen and GHB were not enhanced by rac-BHFF but were enhanced by CGP7930 only at doses that produced hypothermia when given alone. CGP7930-induced hypothermia was not attenuated by the GABA B receptor antagonist 3-aminopropyl(diethoxymethyl)phosphinic acid (CGP35348), at doses that blocked baclofen-induced hypothermia, and was not increased by the nitric-oxide synthase inhibitor N ω-nitro-L- arginine methyl ester, at doses that increased the hypothermic effects of baclofen and GHB. The results provide evidence that CGP7930 and rac-BHFF act in vivo as positive modulators at GABA B receptors mediating loss of righting, but not at GABA B receptors mediating hypothermia. Conceivably, CGP7930, but not rac-BHFF, acts as an allosteric agonist at these latter receptors. Taken together, the results provide further evidence of pharmacologically distinct GABA B receptor subtypes, possibly allowing for a more selective therapeutic interference with the GABA B system.

UR - http://www.scopus.com/inward/record.url?scp=77957231822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957231822&partnerID=8YFLogxK

U2 - 10.1124/jpet.110.171116

DO - 10.1124/jpet.110.171116

M3 - Article

C2 - 20628000

AN - SCOPUS:77957231822

VL - 335

SP - 163

EP - 171

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 1

ER -